Last reviewed · How we verify
Lorcam — Competitive Intelligence Brief
discontinued
lornoxicam
Pain
Small molecule
Live · refreshed every 30 min
Target snapshot
Lorcam (LORNOXICAM). Lorcam works by blocking the COX-2 enzyme, which reduces the production of prostaglandins that cause pain and inflammation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lorcam TARGET | LORNOXICAM | discontinued | lornoxicam |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (lornoxicam class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lorcam CI watch — RSS
- Lorcam CI watch — Atom
- Lorcam CI watch — JSON
- Lorcam alone — RSS
- Whole lornoxicam class — RSS
Cite this brief
Drug Landscape (2026). Lorcam — Competitive Intelligence Brief. https://druglandscape.com/ci/lornoxicam. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab